白细胞分离产物中的单核细胞影响淋巴瘤患者CD19靶向CAR-T细胞治疗的结局
该前瞻性观察研究对95例复发/难治性大B细胞淋巴瘤患者的白细胞分离产物进行转录组和功能评估,发现由T细胞表达的4个髓系基因组成的特征可识别无进展生存期极短的患者,并强调单核细胞对CAR-T疗效的影响。白细胞分离时高循环绝对单核细胞计数也负向影响缓解和PFS。联合评估外周血单核细胞与4基因特征可识别CAR-T后进展风险极高的患者,并提示需纳入单核细胞清除策略以改善CAR-T生产。
要点
- 白细胞分离产物中T细胞表达的4个髓系基因特征可识别CAR-T后PFS极短的患者。
- 白细胞分离时高循环绝对单核细胞计数与缓解和PFS负相关。
- 联合外周血单核细胞与4基因特征可识别CAR-T后进展风险极高的R/R LBCL患者。
核心结论
- 白细胞分离产物中T细胞表达的4个髓系基因特征及白细胞分离时高循环绝对单核细胞计数可识别CAR-T后进展风险极高的R/R LBCL患者。
- 联合评估外周血单核细胞与4基因特征可作为规划比较CAR-T与其他新疗法或异体CAR-T试验的工具。
- 结果强调需纳入单核细胞清除策略以改善CAR-T生产。
研究设计与样本
- 前瞻性观察研究,纳入95例接受tisagenlecleucel或axicabtagene ciloleucel治疗的复发/难治性大B细胞淋巴瘤患者。
- 对白细胞分离产物进行转录组和功能评估,以寻找缓解和生存的相关因素。
主要发现
- 由白细胞分离产物中分离的T细胞表达的4个髓系基因组成的特征可识别无进展生存期极短的患者。
- 白细胞分离时高循环绝对单核细胞计数负向影响缓解和PFS。
- 联合评估白细胞分离时外周血单核细胞与4基因特征可识别CAR-T后进展风险极高的R/R LBCL患者。
临床怎么用
- 作者认为联合评估白细胞分离时外周血单核细胞与4基因特征可用于规划评估CAR-T对比其他新疗法或异体CAR-T的试验。
- 作者指出结果强调需将单核细胞清除策略纳入以改善CAR-T生产。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD19-directed chimeric antigen receptor (CAR) T cells can induce durable remissions in relapsed/refractory large B-cell lymphomas (R/R LBCLs), but 60% of patients do not respond or relapse. Biological mechanisms explaining lack of response are emerging, but they are largely unsuccessful in predicting disease response at the patient level. Additionally, to maximize the cost-effectiveness of CAR T-cell therapy, biomarkers able to predict response and survival before CAR T-cell manufacturing would be desirable. We performed transcriptomic and functional evaluations of leukapheresis products in 95 patients with R/R LBCL enrolled in a prospective observational study, to identify correlates of response and survival to tisagenlecleucel and axicabtagene ciloleucel. A signature composed of 4 myeloid genes expressed by T cells isolated from leukapheresis products is able to identify patients with a very short progression-free survival (PFS), highlighting the impact of monocytes in CAR T-cell therapy response. Accordingly, response and PFS were also negatively influenced by high circulating absolute monocyte counts at the time of leukapheresis. The combined evaluation of peripheral blood monocytes at the time of leukapheresis and the 4-gene signature represents a novel tool to identify patients with R/R LBCL at very high risk of progression after CAR T-cell therapy and could be used to plan trials evaluating CAR T cells vs other novel treatments or allogeneic CAR T cells. However, it also highlights the need to incorporate monocyte depletion strategies for better CAR T production.
引用
- Carniti C, Caldarelli NM, Agnelli L, et al. Monocytes in leukapheresis products affect the outcome of CD19-targeted CAR T-cell therapy in patients with lymphoma. Blood Adv. 2024. PMID: 38359407. doi:10.1182/bloodadvances.2024012563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。